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Non-porous reversed-phase (NP-RP) HPLC has been used to rapidly generate protein profiles of whole cell
lysates of human breast cancer cell lines. The non-porous packing material used was silica coated with C18,
which provided rapid separation with high collection efficiency of proteins from cell lysates. This method
was used to study the differences in protein profiles among normal cells and fully malignant cells that share
a common genetic background. The highly expressed proteins in each cell type were separated and collected
in the liquid state where they were analyzed by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOFMS) to obtain the molecular weight of the proteins. The protein fractions
were then subjected to tryptic digestion and analyzed by pulsed delay extraction (PDE)-MALDI-TOFMS to
obtain the peptide maps. The expressed proteins were identified based upon the molecular weight and
peptide map using database-searching procedures. It is shown that key cancer-related proteins can be
detected and identified which may be potentially used as biomarkers for cancer detection. Copyright
# 1999 John Wiley & Sons, Ltd.
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The transformation of cells into malignant cancer depends
on genetic mutations. These mutations lead to the activation
of cellular oncogenes that take over the processes in the cell
transforming it into an entity that continues to survive and
proliferate. In turn this transformed cell may undergo
further mutations and develop into a fully malignant tumor
cell. Although these changes in the cell occur at the DNA
level, they must ultimately be expressed in terms of the
protein content of the cell. Small mutations in the DNA may
manifest themselves as large changes in the resulting protein
cascades that control various functions in the cell. Many of
the mutations that occur in the DNA result in post-
translational changes in the proteins that cannot be predicted
from the DNA information. Thus, changes in the cell that
result from malignant transformation are often best
followed by monitoring changes in the protein expression
that results.
The traditional method of studying changes in cellular
protein expression has been two-dimensional polyacryl-
amide gel electrophoresis (2-D PAGE).1–5 More recently,
several liquid phase based techniques have been developed
for the separation of proteins.6–16These methods include the
use of liquid chromatography, which allows a means of
separating and isolating proteins in the liquid phase.6–16
Reversed-phase (RP) C18 column separations have been
used to separate proteins from whole cell lysates of bacterial
cells16 and from human lymphocyte nuclei.12 The use of
such chromatographic separations allows the rapid screen-
ing of proteins from whole cell lysates on a time scale of less
than an hour as compared with the extended time required
running a 2-D gel. The use of liquid phase separations also
provides proteins in the liquid phase that can be more easily
analyzed by mass spectrometry.
In recent work, non-porous reversed-phase (NP-RP) high
performance liquid chromatography (HPLC) has been used
for separations of whole cell lysates of bacterial16 cells and
human erythroleukemia (HEL) cells.10 The use of these
non-porous, C18 coated, silica-based packing materials has
been shown to provide important advantages in the
separations of protein mixtures compared with the porous
columns. The NP-RP-HPLC separations showed excellent
resolution for separations of proteins in less time than the
porous columns. Separations of whole cell lysates using the
non-porous columns can be performed in typically 15–30
minutes. The use of non-porous packing avoids the problem
of proteins sticking inside the pores of porous materials and
thus considerably improves the resolution and protein
recovery.
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In this work, we useNP-RP-HPLCto rapidly separate
proteins from wholecell lysatesof breastcancercell lines.
The MCF-10 cell lines examined in this work havebeen
developed based upon spontaneous immortalization of
breast epithelial cells obtained from a patient with
fibrocystic disease.17 Sinceall cell lines examined in this
work were derived from a single patient, irrelevant
differencesin geneexpressionshouldbe minimized. The
NP-RP-HPLC method is thus used to rapidly screenthe
proteinsfrom wholecell lysates of two malignantcell lines
andonenormal(immortalized)cell line. Themethodis used
to searchfor elevatedlevels of proteinsor theappearanceof
new proteinsin the malignantcells as comparedwith the
normal cells. It is shown that severalkey cancer-related
proteins, including p53,18–26 c-src,27–29 c-myc,30–32 andh-
ras,30,33 are observed in the malignant cell lines at highly
elevatedlevelscomparedwith thenormalcells.In addition,
the protein-containing liquid can be collected following
separation and analyzed after tryptic digestion using
MALDI-TOFMS. Theresulting peptide mapcanbeentered
into the MS-Fit of the Protein Prospector Databasefor
identification. It is demonstratedthat NP-RP-HPLC of
whole cell lysates with analysesby MAL DI-TOFMS may
serve asa powerful tool for rapidmonitoring of changes in
oncogene expressionin human breastcarcinoma.
EXPERIMENTA L
Chemicals
The chemicals involved in this study were usedwithout
prior purification. Acetone (HPLC grade) was obtained
from Fisher(Fair Lawn, NJ, USA). Acetonitrile, guanidine
hydrochloride (gu-HCl), a-cyano-4-hydroxycinnamic acid
(a-CHCA), trifluoroaceticacid (TFA) andoctyl glucopyr-
anoside (OCG)werefrom Aldrich (Milw aukee,WI, USA).
Trypsin wasacquired from Promega(Madison, WI, USA).
Distilled anddeionizedwaterwasobtained from a Mill i-Q
reagentgradepurification systemfrom Millipor e (Bedford,
MA, USA). The nitrocellulose(NC) used,Immobilon-NC
Pure,wasalsofrom Mill ipore.
Cell cultures
The MCF-10 cell samples used in these experiments
originated by spontaneous immortalization of breast
epithelial cells from a fibrocystic patient.17 Immortalized
MCF-10A cells are not transformed and share many
properties with normal breast epithelial cells. Fully
malignant, metastatic variants, MCF-10 Cala and Cald,
were also derived from the same source.34 Cells were
maintained in a humidified CO2 incubator at 37°C and
adherent cells harvested in log phase(70–80%conflu-
ence).In order to harvestthe cells, the growth mediawas
aspirated and the cells gently washedwith PBS, prior to
scraping with a rubberpoliceman.The cells wereimmedi-
ately frozen(ÿ80°C) uponremovalfrom the tissueculture
dishes.
Matr ix, substrate and samplepreparation
a-CHCA was the matrix used in theseexperiments. For
MALDI analysis, the matrix was preparedas a saturated
solution in a4:1ratioof acetoneto Milli-Q watercontaining
0.1 to 0.5 % TFA. Before applying the samplesolution to
thesteelprobetip, 2 mL of nitrocellulose(NC;10mg/mL
in acetone)were appliedto the tip and allowed to air dry
followed by 3–5mL of samplesolution, which were also
allowed to air dry. The final stepinvolved the addition of
4 mL of matrix solution ontotheprobetip thatwerealso air
dried.
The cell pellets were lysed in 200mL of 50mM Tris
buffer (pH 7), 6 M gu-HCl and 5–10mM OCG. This
mixture was vortexed for 30s and stored overnight at
ÿ20°C. Subsequently, the lysate was fractionated by
centrifugation in an Eppendorf centrifuge at 16500 rpm
for 20min. In orderto removeasmuchparticulateandcell
debris as possible, the soluble portion was centrifuged at
16500 rpm for another 10min. The most reproducible
results were observed when the soluble portion was
analyzedwithin 24 h.
UsingaSpeed-Vac thetotal volumeof theNP-RP-HPLC
collected fractions was reduced to 10–20mL in order to
remove the acetonitrile and TFA. Then 10mL of 50mM
ammonium bicarbonatewereaddedto eachfraction andit
was vortexed. Finally, 2 mL of the sequencing grade
modified trypsin (0.5mg/mL) wereaddedto the fractions.
Again themixtureswerevortexedandincubatedat37°C for
24 h.
Af ter tryptic digestion, the resulting peptides were
subjectedto PDE-MALDI analysisto obtainpeptide maps.
In the PDE-MALDI analysis, one part of the saturated
matrix solutionwasdiluted 10fold, i.e.9mL of acetone(0.1
to 0.5% TFA) wereaddedto 1 mL of matrix solution. Then
2 mL of this diluted matrix solutionwereaddeddirectly to
the probetip. To improve the PDE-MALDI massspectra,
the peptide solutiongeneratedby tryptic digestionwasre-
acidified by adding2 to 5mL of Mill i-Q water(0.1% TFA).
Then8 mL of this acidified digestsolutionweremixedwith
1 mL of the diluted matrix solution. This mixture was
vortexed,and3mL wereappliedto the dried matrix layer.
When this layer was dry, another 3 mL were addedand
dried.This procedurewasrepeatedseveraltimes.
NP-RP-HPLC analysis
A Beckman(Fullerton, CA, USA) SystemGold1 HPLC
was utilized for this work. The pump (Model 128) hasa
gradient solvent delivery module with built-in system
controller. Thedetectoris a programmable detector module
(Model 166) with an analytical flow cell. The deuterium
lamp provides a wide range of detection from 190 to
700nm. All separations in this work were monitored at
214nm.Thecolumnwasprovidedby MICRA (Northbrook,
IL, USA). It contained non-porous silica bead packing
material of 1.5mm particlediametercoatedwith C18. The
dimensionof thecolumnwas4.6 33mm wherethewide-
borecolumnwasnecessary to collect anadequateamountof
material andthe short lengthallowedfor rapid separations
on the order of minutes. The RP-HPLC separations of
proteinsin thetumorcell lysate wasperformedvia gradient
elutionof two solvents(solventA: Milli-Q waterwith 0.1%
TFA; solvent B: acetonitrile with 0.1 % TFA) with a flow
rateof 1 mL/min wherethe temperatureof the non-porous
column wasmaintainedat 60°C in a Timberline (Boulder,
CO, USA) column heater.The gradient profile used for
solventB wasgenerally asfollows: 0 % for 1.5min; 0 to 10
% in 2 min; 10to 60% in 25min; 60to 80% in 5 min; 80to
100 % in 1 min; 100 % for 2 min; 100 to 0 % in 1 min. In
orderto obtaina reproducibleseparationprofile, thesample
was‘conditioned’ to thecolumnenvironmentby mixing the
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samplewith anequivalentamount of water(0.1% TFA), or
a 1:1 ratio. This acidifying step was performed prior to
sample injection. Each injection contained an averageof
50mg of protein. Thefractionscollectedweresubsequently
subjectedto MALDI analysisto size the protein masses.
Each of the peaks contained an average of 1–5mg
available for analysisafter collection. The fractions were
then digestedby trypsin before undergoing PDE-MAL DI
analysis to obtaintheir peptidemaps.
MA LDI massspectral analyses
The TOF mass spectrometeremployedin thesestudieswas
a modified Wiley-McLaren design with a four-plate
acceleration stage.35 It was capable of high voltage
accelerationup to20kV (R. M. JordanCo.,GrassValley,
CA, USA). The lasersource usedto produce MALDI wasa
Minilite1 10Hz Nd:YAG lasersystem(Continuum,Santa
Clara, CA, USA). All massspectrawere obtained using
355nm radiation. Thelaserpower density wasestimatedat
5 106 to 1 107 W/cm2. The detector was a triple
microchannel plate (MCP) detector (R. M. Jordan Co.)
which adapted a CuBe conversion dynode with post-
acceleration (PA) capability up to 12kV36 in front of
theMCP. The total ion accelerationacrosstheTOF device
may thusbe>30kV. ThePA stageenhancesthe detection
of heavy species, but at the expenseof resolution. In
addition, pulseddelayed extraction (PDE) as described in
previous studies37–41 could be used to enhance the
resolution for the analysis of the tryptic digests.The 1-m
long flight tubewaspumpedto a basepressureof 8 10ÿ7
to 1 10ÿ6 Torr by a diffusion pump (Varian Inc.,
Lexington, MA, USA). Datawasrecordedusinga LeCroy
9310AM (400MHz) digital oscilloscope (LeCroy Corp.,
Chestnut Ridge, NY, USA) and was processed on a
Gateway586computer.
Database-searching procedure for protein identification
The MS-Fit sequence databaselocated in the Protein
Prospector programwasusedfor protein identification by
enteringthe peptide massesgenerated by tryptic digestion.
The programis available on the Internet.42 Subsequently,
otherrelevant parameterssuchasproteinspecies, molecular
weight and pI rangeare also enteredin order to narrow
downthesearch. In this case,Homosapienswaschosen as
thespecies. Sincetheseproteinswereobtainedfrom HPLC,
no pI information wasavailable. Thus,thepI rangewasset
between3 and10.Therangeof molecular weightvaluesfor
each search was determined by MALDI analysis. The
Figure 1. (a)NP-RP-HPLCproteinprofile: malignanthumanbreastcell lysate(calaCL1).(b) NP-RP-HPLCproteinprofile: malignanthumanbreast
cell lysate(caldCL1).(c) NP-RP-HPLCproteinprofile: normal(immortalized)humanbreastcell lysate(10A).
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tolerancefor thesearchof peptidesagainstthedatabasewas
setbetween 5 and30 Da.
RESULTS AND DISCUSSION
Figures 1(a)–(c) show the protein profiles of whole cell
lysates of the MCF-10basedbreast epithelial cell lines for
two different cell lysatesof malignantcell lines (Figs1(a),
(b)) and for the normal immortalized cell line (Fig. 1(c)).
The gradient(between10 and 60 % B) is shown in each
figure where the expressedpeaksof interest are labeled
basedupon the percent acetonitrile as they eluted. Since
different gradients were run in each case,the time axis
cannot be used as a means of comparison in these
separations. Eachof the labeledpeakswas collected as a
fraction in the liquid stateandpartof the fractionwasused
to obtain the molecular weight by MALDI -TOFMS. The
remainder was subjected to tryptic digestion and the
resulting tryptic mapwasenteredinto theMS-Fit Database
to identify these proteins.
The protein profiles generated by NP-RP-HPLC clearly
show large differences in the proteins expressed in the
malignant cells (Figs 1(a) and (b)) as compared with the
normalcells(Fig.1(c)).Theproteinsidentifiedusing tryptic
digestionarelisted in Table1, while thedifferences in peak
expressionlevel (or relative peakabsorbance)between the
two malignantcell linesandnormal cell line aretabulatedin
Table2. Thedistinctivefeaturein themalignantcancercell
lines is the overexpressedpresenceof p53 (peak 7) and
proto-oncogenetyrosine kinase SRC (c-src) (peak 8) as
compared with normal cells. In addition, other proteins
often associatedwith cancer progression suchasc-myc,h-
ras and various related proteins are also observed. In
particular, thep53peakservesasadistinctive markerof the
cancer cells.It is known thatp53is expressed at high levels
in a number of tumor types andits overexpressionis often
an indicator of unfavorable prognosis for several cancers
including breast cancer.43–45 As a key tumor suppressor
protein, p53 plays an important role in regulating the cell
cycle andnormalcell growth.18–20Thelossof p53function
dueto a variety of mutations in different typesof canceris
believed to beasignificant factorin theunrestrainedgrowth
of cancercells. All normal cells have low levels of p53.
However,mutationsin p53canincreaseits half-life from 20
minutesto several hours, thusresulting in accumulation of
p53 in cancercells.23 The levels of p53 detected in these
breastcancer cell linesclearlydominatetheproteinprofiles
under 80 kDa. It is not knownat presentfrom theMALDI-
TOFMS peptide map datawhetherthe p53 is the wild or
mutant form. In order to determine the presenceof either
point mutationsor phosphorylations, moredetailedsequen-
cing procedures will be required.
In addition,c-srcis anoncoproteinof thekinasetypethat
is observedin boththemalignantcancercell lines(Figs1(a)
and (b)) but is not observedat comparable levels in the
normal cell protein profile of Fig. 1(c).Mutationsof srcare
believed to be involved in cell transformation and its
overexpression results from the phosphorylation of target
proteins.27–29 This transformation may be due to the
increasedlevel of phosphorylation, or a changein the site
of phosphorylation may be involved. Moreover, src is able
to phosphorylate itself and the stateof phosphorylation of
src may be important in its transforming activity. The
MALDI peptide mapin this work did not provide sufficient
information to determine where the src was mutated.
Nevertheless, thepresenceof c-srcin thecancer cell protein
profiles in this work makesit a potentialmarkerfor cancer
detection.
An importantaspectof Figs1(a)and(b) is that thereare
distinct differences in protein expression for the two
malignant cancer cell lines, even though they were
developed from a common genetic background.In Fig.
1(a), in thecalaCL1cell line, therearestrongpeaksfor the
L-myc proto-oncogeneprotein and the c-myc promoter
protein; whereas in the caldCL1 cell li ne (Fig. 1(b)) these
two proteins are less expressed. Thus, multiple genetic
pathways can be taken in the progressionto malignancy.
The c-myc is animportantoncogenethatmaybeimportant
Table 1. Oncoproteins identified by the MS-Fit databasesearchingprocedure and their molecular weights
Peak Proteinname Mol. wt. (kDa) Accessionnumber
1 TransformingproteinP21(c-h-ras) 21.3 P01112
2 Ras-relatedproteinRAB-6 23.5 P20340
3 Prohibition 29.8 P35232
C-myc promoterprotein 37.0 P22712
4 L-myc-1 proto-oncogeneprotein 40.3 P12524
JNK activatingkinase1 44.2 P45985
5 P53regulatedPA26-73nuclearprotein 49.6 AADO4811
6 BreastepithelialantigenBA46 43.1 Q08431
7 Phosphoproteinp53 43.6 P04637
8 Proto-oncogenetyrosinekinaseSRC(c-src) 59.8 P12931
Table 2. Comparison of relative peak absorbance(or expression
level)of the detectedoncoproteins:Peaksfrom malignant
cell lysates (calaCL1 and caldCL1) versus peaks from
normal cell lysate (10A)









Note: () means more highly expressedthan 10A, (ÿ) meanslessexpressed
than 10A. ‘Similar’ means that the expressionlevel is similar in both the
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in the development of tumors. However, alternative
oncogenes or other factors may provide alternative
mechanismsfor carcinogenesi in thesebreast cancercell
lines. In bothcell lines theoverexpression of p53andc-src
still remain as possible biomarkers for the detectionand
prognosisof thesetypes of tumor.
In conclusion,NP-RP-HPLCprovidesa rapidmethodfor
separationof proteinsfrom wholecell lysatesof cancercell
lines. This methodcan be usedwith MALDI -TOF mass
spectral analysis to identify highly expressed proteins,
which are biomarkers for carcinogenesis. Theseproteins
includetheimportanttumorsuppressor p53andwell-known
oncogenessuchasc-src,c-myc,h-rasandrelatedproteins.It
has been shown that there are large differences in the
expressionof p53 andc-srcbetween the normal(immorta-
lized) breastepithelial cell line and the fully malignant
species. Further, there are salient differences in the
expressionof different oncogenesbetweenthe two related
breast cancer cell lines studied. The presenceof p53 and
thesekeyoncogenesmayserveasimportantbiomarkersfor
detection andprognosisof tumorsin future studies.
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